华东医药：DR10624注射液临床试验申请获批准

Core Viewpoint - The company has received approval for clinical trials of its drug candidate DR10624, which targets hypertriglyceridemia (HTG) [1] Group 1 - The company's subsidiary, Zhejiang Daor Biotechnology Co., Ltd., has been granted the Clinical Trial Approval Notice by the National Medical Products Administration [1] - The approved clinical trial will allow the company to proceed with testing the efficacy and safety of DR10624 injection [1] - The indication for the drug candidate is specifically for high triglyceride levels in the blood [1]